From the American Academy of Ophthalmology

This head-to-head comparison finds that bevacizumab was noninferior to ranibizumab for BCVA and that the drugs had similar safety profiles. The GEFAL study was a prospective, double-masked, randomized clinical trial including 501 patients enrolled at 38 centers in France. Subjects were randomly assigned to receive 1.25 mg bevacizumab or 0.50 mg ranibizumab. At one year, the difference in mean change in BCVA was +1.89 letters. The number of injections was similar for both drugs. Safety profiles also were similar, with no differences in safety noted or new concerns identified. Ophthalmology, November 2013